Isocitrate dehydrogenases (IDHs) are pivotal enzymes in the tricarboxylic acid cycle, catalysing the oxidative decarboxylation of isocitrate to α-ketoglutarate with concomitant reduction of ...
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study Twenty-three patients received ...
Somatic monoallelic single nucleotide variants in the genes that encode isocitrate dehydrogenase (IDH) 1 and 2 are found in a large subset of diffusely infiltrating gliomas and subsets of acute ...
The global isocitrate dehydrogenase (IDH) inhibitors market, valued at USD 1.7 billion in 2022, is poised for explosive growth, projected to reach an astounding USD 39.16 billion by 2033. This ...
Vorasidenib is an investigational oral, selective, highly brain-penetrant dual inhibitor of IDH1/2 enzymes. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug ...
The isotrate dehydrogenase (IDH) inhibitors market sales is predicted to expand from US$ 1.7 billion in 2022 to US$ 39.16 billion in 2033, with a compound annual growth rate (CAGR) of 33% from 2023 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results